Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Longo

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 21, 2017
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)Alfredo Carrato, Albert Abad, Bartomeu Massuti, et al.
Cancer|February 7, 2023
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 studyDo-Youn Oh, Alain Algazi, Jaume Capdevila, et al.
Nature Cancer|February 20, 2025
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trialAurelien Marabelle, David M O'Malley, Andrew E Hendifar, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2022
Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 studyMichele Maio, Mayur M Amonkar, Josephine M Norquist, et al.
Cancers|August 7, 2021
Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient TumorsEdouard Auclin, Perrine Vuagnat, Cristina Smolenschi, et al.
Plos One|October 25, 2016
Menstrual and Reproductive Factors and Risk of Gastric and Colorectal Cancer in SpainVirginia Lope, Nerea Fernández de Larrea, Beatriz Pérez-Gómez, et al.
Cancers|September 28, 2021
Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS StudyPilar García-Alfonso, Andrés Muñoz, Jerónimo Jiménez-Castro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2025
Phase II study of perioperative Avelumab plus chemotherapy for patients with resectable gastric cancer or gastroesophageal junction cancer - the MONEO StudyMaria Alsina, Guillermo Villacampa, Carlos de Andrea, et al.
Journal of Geriatric Oncology|December 16, 2017
Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysisLaura Visa, Paula Jiménez-Fonseca, Elena Asensio Martínez, et al.
Future Oncology (London, England)|February 16, 2021
Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS studyFederico Longo, Mónica Jorge, Ricardo Yaya, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|June 21, 2017
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)Alfredo Carrato, Albert Abad, Bartomeu Massuti, et al.
Cancer|February 7, 2023
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 studyDo-Youn Oh, Alain Algazi, Jaume Capdevila, et al.
Nature Cancer|February 20, 2025
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trialAurelien Marabelle, David M O'Malley, Andrew E Hendifar, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2022
Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 studyMichele Maio, Mayur M Amonkar, Josephine M Norquist, et al.
Cancers|August 7, 2021
Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient TumorsEdouard Auclin, Perrine Vuagnat, Cristina Smolenschi, et al.
Plos One|October 25, 2016
Menstrual and Reproductive Factors and Risk of Gastric and Colorectal Cancer in SpainVirginia Lope, Nerea Fernández de Larrea, Beatriz Pérez-Gómez, et al.
Cancers|September 28, 2021
Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS StudyPilar García-Alfonso, Andrés Muñoz, Jerónimo Jiménez-Castro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2025
Phase II study of perioperative Avelumab plus chemotherapy for patients with resectable gastric cancer or gastroesophageal junction cancer - the MONEO StudyMaria Alsina, Guillermo Villacampa, Carlos de Andrea, et al.
Journal of Geriatric Oncology|December 16, 2017
Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysisLaura Visa, Paula Jiménez-Fonseca, Elena Asensio Martínez, et al.
Future Oncology (London, England)|February 16, 2021
Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS studyFederico Longo, Mónica Jorge, Ricardo Yaya, et al.
Pageof 7